CTO-20190135

Inclusion Criteria:

* Men or women greater than or equal to 18 years old.
* Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements. In the United States, this test must be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.

Exclusion Criteria:

* Primary brain tumor.
* Spinal cord compression, or untreated, or symptomatic, or active brain metastases, or leptomeningeal disease from non-brain tumors.
* Myocardial infarction within 6 months of study day 1.
* Gastrointestinal (GI) tract disease causing the inability to take oral medication.

Any Site

Indiana University (IU)

• Glick Eye Institute (IU Health)
• Indiana University Hospital / IU Simon Cancer Center

• Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
  Kuboki Y;Fakih M;Strickler J;Yaeger R;Masuishi T;Kim EJ;Bestvina CM;Kopetz S;Falchook GS;Langer C;Krauss J;Puri S;Cardona P;Chan E;Varrieur T;Mukundan L;Anderson A;Tran Q;Hong DS;